Key result
VerifyNow P2Y12 shows a ~0.7 correlation with light transmission aggregometry for assessing platelet function.
Why the study?
Does the VerifyNow P2Y12 point-of-care device correlate with light transmission aggregometry for monitoring platelet function in subjects treated with prasugrel or clopidogrel?
Population
591 subjects from an integrated database of 8 clinical trials, including healthy subjects, patients with…
Comparison
VerifyNow P2Y12 point-of-care device to monitor… vs Light transmission aggregometry method
Design
Meta-analysis
Authors
Loading...
Supports VerifyNow for point-of-care P2Y12 monitoring in prasugrel- or clopidogrel-treated patients; confirms correlation with light transmission aggregometry.
Meta-Analysis (n=591)
Yes
Does the VerifyNow P2Y12 point-of-care device correlate with light transmission aggregometry for monitoring platelet function in subjects treated with prasugrel or clopidogrel?
Effect estimate: r ~0.7
The VerifyNow P2Y12 point-of-care device correlates well with light transmission aggregometry for assessing platelet inhibition by prasugrel and clopidogrel, supporting its clinical utility.
Jakubowski et al. (2010) conducted a meta-analysis in Healthy subjects, coronary artery disease, end-stage renal disease, and acute coronary syndrome (n=591). VerifyNow P2Y12 point-of-care device vs. Light transmission aggregometry was evaluated on Platelet function results (platelet inhibition) (r ~0.7). The VerifyNow P2Y12 point-of-care device and light transmission aggregometry showed well-correlated platelet function results (r ~0.7) in subjects treated with prasugrel or clopidogrel.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: